Skip Navigation Links

Research Inputs

OCT uses three sources for compounds:

The first source is OCT’s library of proprietary and patentable derivative cannabinoid compounds, created and optimised for evaluation across a range of large indications. 

OCT has developed an extensive library of proprietary compounds. The latest medicinal chemistry techniques are utilized to develop cannabinoid derivatives that harnesses the therapeutic potential of cannabinoids, while improving properties such as efficacy, toxicity and bioavailability.

These compounds are being screened in a number of disease model assays. Promising hits will be developed into lead compounds for pre-clinical development followed by clinical trials.

The second source is unmodified natural compounds (most often phytocannabinoids) and off-patent compounds that will be developed for rare diseases under orphan drug programs. 

There is an increasing body of evidence showing the strong medical potential of phytocannabinoids. Examples include, but are not limited to, THC and CBD for pain relief, as well as CBD to increase survival in animal models with pancreatic cancer. OCT’s phytocannabinoid research programme includes compounds such as CBD and CBG, but also rare cannabinoids, such as CBN. Phytocannabinoids are being tested in a range of assays in various disease models to explore their full potential as therapies. 

The third source is in-licensed compounds from third-parties for development in both large markets and orphan indications. OCT has completed in-licensing of one molecule, OCT461201. OCT462101 has shown efficacy in inflammatory bowel disease pain models and in entering pre-clinical development in Q4 2019.

By utilising these three strategies, OCT is creating a portfolio that balances long-term market value with time to market and ensures intellectual property protection across all activities.